

# Sharing Experiences in Prostate Cancer

MD Anderson Cancer Center Madrid  
Certified Preceptorship

9 th and 10 th of July  
3rd and 4th of September  
Madrid, 2021

## Aims of the Preceptorship

- Comprehensive summary of molecular biology behind the development of prostate cancer.
- Sharing experiences about 'real life' management of prostate tumors patients.
- Summary of current clinical trials ongoing in prostate tumors field.
- Increase the knowledge of new molecular biomarkers and predictors of response in Oncology.
- Share the current management in multidisciplinary teams for patients decision-making process.
- Compare different approaches to cancer patients' treatments between attendees' institutions and MD Anderson Cancer Center Madrid.
- Think 'out of the box': What's next in Oncology?

## Target audience


- Group of 15-25 physicians with a minimum of 4 years' oncology patient care experience.
- High interest in prostate tumors field.
- High interest in leverage knowledge in Oncology.
- Open mind to think of new perspectives.

Promoted by

MD Anderson  
Cancer Center  
Fundación • España

Sponsors

Janssen



MD Anderson  
Cancer Center  
Madrid • España

**12:00 - 12:10 Welcome & Introduction to the course**

*Dr. Enrique Grande*  
Head of Medical Oncology Service.  
MD Anderson Cancer Center Madrid.

**12:10 - 12:40 A comprehensive summary of the molecular biology that Oncologists and Urologists should be aware of in Prostate cancer.**

*Dr. Enrique Grande*  
Head of Medical Oncology Service. MD Anderson Cancer Center Madrid.

## LOCALIZED DISEASE

**12:40 -13:00 Active Surveillance: based on a clinical case to define the profile**

*Dr. Fernando Lista*  
Urology at MD Anderson Cancer Center Madrid.

**13:00 -13:20 Role of Radiotherapy: based on a clinical case to define the profile**

*Dr. Juan Carlos Viera*  
Radiation Oncology at MD Anderson Cancer Center Madrid.

**13:20 - 13:40 Role of Surgery: based on a clinical case to define the profile.**

*Dr. Fernando Lista*  
Urology at MD Anderson Cancer Center Madrid.

**METASTATIC HORMONE-SENSITIVE SETTING****9:00 - 9:40 "What we should do with Oligometastasis: from theory to clinical practice**

*Dr. Juan Carlos Viera*  
Radiation Oncology at MD Anderson Cancer Center Madrid.

**9:40 - 10:10 "Chemotherapy vs Novel targeted agents**

*Dr. Enrique Grande*  
Head of Medical Oncology Service. MD Anderson Cancer Center Madrid.

**10:10 -10:40 "Dissecting Apalutamide in the Hormone-sensitive stage**

*Dr. Enrique Grande*  
Head of Medical Oncology Service. MD Anderson Cancer Center Madrid.

10:40 - 11:00 DISCUSSION

**11:00 -11:30 "Interactive Clinical Case Presentation about patient selection for the different alternatives in the Hormone-Sensitive setting**

*Dr. Enrique Grande*  
Head of Medical Oncology Service. MD Anderson Cancer Center Madrid.

11:30 - 12:00 DISCUSSION

**METASTATIC HORMONE-SENSITIVE SETTING****"What are the main challenges to face in a Genitourinary Tumor Board**

*Dr. Enrique Grande*  
Head of Medical Oncology Service. MD Anderson Cancer Center Madrid.

**"Can we do things different in our site? The challenge and experience in a multidisciplinary Prostate Cancer Consultation**

*Dr. Teresa Alonso*  
Medical Oncology at Hospital Ramón y Cajal, Madrid.

DISCUSSION 12:50 - 13:20

**NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER: DOES IT REALLY EXIST?****"A practical approach to M0 castration resistant setting at MD Anderson Cancer Center Madrid**

*Dr. Enrique Grande*  
Head of Medical Oncology Service. MD Anderson Cancer Center Madrid.

DISCUSSION 13:50 - 14:30

**METASTATIC CASTRATION RESISTANT PROSTATE CANCER: EVOLVING LANDSCAPE****"Is there any better sequencing of treatments in the metastatic CRPC field?**

*Dr. Álvaro Pinto*  
Medical Oncology at Hospital La Paz, Madrid.

**"Role and Challenges of Precision Medicine in Prostate Cancer**

*Dr. Enrique Grande*  
Head of Medical Oncology Service. MD Anderson Cancer Center Madrid.

DISCUSSION 10:30 - 11:00

**"Interactive Clinical Case Presentation about patient selection for the different alternatives in the Castration-Resistant setting**

*Dr. Álvaro Pinto*  
Medical Oncology at Hospital La Paz, Madrid.

DISCUSSION 11:30 - 12:00